Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF

Transfusion and Apheresis Science

Volumn 40, Issue 2, 2009, Pages 91-95

  Callera, Fernando ^a   Cavenaghi, Luciana ^a   de Melo, Cláudio M T P ^a  

^a Serviço de Hematologia e Hemoterapia de São José Dos Campos   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG MEGADOSE; FEMALE; HUMAN; LEUKAPHERESIS; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ADULT STEM CELLS; AGED; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 62949170602     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2009.01.015     Document Type: Article

References (24)

1. Milone G., Leotta S., Indelicato F., Mercurio S., Moschetti D., Di Raimondo F., et al. G-CSF alone vs. cyclophosphamide plus G-CSF in peripheral blood PBPC mobilization of patients with lymphoma: results depend on degree of previous treatment. Bone Marrow Transplant 31 (2003) 747-754
2. Pavone V., Gaudio F., Guarini A., Perrone T., Zonno A., Curci P., et al. Mobilization of PBPCs with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in NHL. Bone Marrow Transplant 29 (2002) 285-290
3. Pardee T.S., Hagag N., and Singh B. Effective CD34+ stem cell mobilization with low-dose pegfilgrastim. J Appl Res 6 3 (2006) 196-200
4. Ahn J.S., Park S., Im S.A., Yoon S.S., Lee J.S., Kim B.K., et al. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Kor J Internal Med 20 3 (2005) 224-231
5. Ketterer N., Salles G., Moullet I., Dumontet C., ElJaafari-Corbin A., Tremisi P., et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignances. Brit J Haematol 10 (1998) 235-242
6. Canales M.A., Fernandez-Jimenez M.C., Martin A., Arrieta R., Caballero M.D., Diez J., et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 86 (2001) 4949-4958
7. Meisenberg B., Brelim T., Schmeckel A., Miller W., and McMillan R. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 38 2 (1998) 209-215
8. Alegre A., Tomás J.F., Martínez-Chamorro C., Gil-Fernández J.J., Fernández-Villalta M.J., Arranz R., et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high dose cyclophosphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 20 (1997) 211-217
9. Desikan K.R., Barlogie B., Jagannath S., Vesole D.H., Siegel D., Fassas A., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 6 (1998) 1547-1553
10. Bellido M., Sureda A., Martino R., Madoz P., Garcia J., and Brunet S. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Haematologica 83 5 (1998) 428-431
11. Jantunen E., Putkonen M., Nousiainen T., Pelliniemi T.T., Mahlamaki E., and Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 31 5 (2003) 347-351
12. Watts M.J., Sullivan A.M., Jamieson E., Pearce R., Fielding A., Devereux S., et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma. J Clin Oncol 15 2 (1997) 535-546
13. Deliliers G.L., Annaloro C., Marconi M., Soligo D., Morandi P., Luchesini C., et al. Harvesting of autologous blood stem cells after a mobilizing regimen with low-dose cyclophosphamide. Leukemia Lymphoma 43 10 (2002) 1957-1960
14. Sutherland H., Eaves C., Lansdorp P.M., Phillips G.L., and Hogge D.E. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 83 12 (1994) 3808-3811
15. Stadmauer E.A., Schneider C.J., and Silberstein L.E. Peripheral blood progenitor cell generation and harvesting. Sem Oncol 22 (1995) 291-300
16. Fielding A.K., Watts M.J., and Goldstine A.H. Peripheral blood progenitor cells versus bone marrow. J Hematother 3 (1994) 203-211
17. Siena S., Bregni M., and Gianni M.A. Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients. Exp Hematol 21 (1993) 203-205
18. Smith A.M. Peripheral blood progenitor cell transplantation: clinical, practical and economics considerations. J Haematol 3 (1994) 331-348
19. Mavroudis D., Read E., Cottler-Fox M., Couriel D., Molldrem J., Carter C., et al. CD34+ cell dose predicts survival, post transplant mortality and rate of hematologic recovery after allogenic marrow transplants for hematologic malignances. Blood 88 (1996) 3223-3229
20. Taylor P.R.A., Jackson G.H., Lennard A.L., Lucraft H., and Proctor S.J. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. Newcastle Northern Region Lymphoma Group Brit J Cancer 67 (1993) 383-387
21. Gratama J.W., Sutherland D.R., and Keeney M. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells. Sem Hematol 38 (2001) 139-147
22. Ayello J., Semidei-Pomales M., Preti R., Hesdorffer C., and Reiss R.F. Effects of long-term storage at -90 °C of bone marrow and PBPC on cell recovery, viability, and clonogenic potential. J Hematother 7 4 (1998) 385-390
23. Moskowitz C.H., Glassman J.R., Wuest D., Maslak P., Reich L., Gucciardo A., et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4 2 (1998) 311-316
24. Assouline S., Sylvestre M.P., Carriere P., Shustik C., and Laneuville P. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignances and high-dose cyclophosphamide: a retrospective review of 141 patients. Transfusion 46 (2006) 174-179